Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.

CanGaroo Bio Envelopes are a natural extracellular matrix (ECM) scaffold that securely hold cardiovascular implantable electronic devices (CIEDs) to create a stable environment following implantation. In vivo studies have demonstrated that use of CanGaroo when implanting CIEDs reduces the risk of device migration and erosion and may facilitate device removal when future exchange or revision is required.

“BIOTRONIK is trusted and respected by hospitals, physicians and patients, and our distribution partnership expands access to a meaningful cardiovascular solution,” said Andrew Green, Aziyo’s EVP and General Manager of Cardiovascular Products. “Our ECM envelopes help deliver the best possible patient care and can reduce cost, providing advantages that complement BIOTRONIK’s comprehensive portfolio of cardiac rhythm management devices. This partnership changes the landscape of cardiac care.”

CanGaroo is available in five sizes for use with the full spectrum of transvenous and subcutaneous CIEDs. Per the strategic distribution agreement, BIOTRONIK is selling all five sizes in the United States branded as Bio Envelope.